A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT ID: NCT02956122

Last Updated: 2021-01-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-04-26
• Study Completion Date: 2018-05-03

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.

Conditions

Graft Versus Host Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Study Part 1 - All Participants - GLASSIA

Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)

Group Type: EXPERIMENTAL

GLASSIA

Intervention Type: BIOLOGICAL

GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]

methylprednisolone or equivalent steroid

Intervention Type: DRUG

The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Study Part 2 - GLASSIA

Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)

Group Type: EXPERIMENTAL

GLASSIA

Intervention Type: BIOLOGICAL

GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]

methylprednisolone or equivalent steroid

Intervention Type: DRUG

The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Study Part 2 - Albumin (Control)

Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)

Group Type: PLACEBO_COMPARATOR

methylprednisolone or equivalent steroid

Intervention Type: DRUG

The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Albumin

Intervention Type: BIOLOGICAL

The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).

Interventions

GLASSIA

GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]

Intervention Type: BIOLOGICAL

methylprednisolone or equivalent steroid

The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Intervention Type: DRUG

Albumin

The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).

Intervention Type: BIOLOGICAL

Other Intervention Names

as alpha-1 antitrypsin; A1PI; alpha-1 proteinase inhibitor; Human Albumin

Eligibility Criteria

Inclusion Criteria

1. Male or female participants aged ≥18 years at the time of screening

2. Recipient of an hematopoietic stem cell transplantation (HSCT)

3. The disease indication for which the participant required HSCT must be in remission

4. Newly diagnosed acute graft-versus-host disease (GvHD), including lower Gastrointestinal (GI) involvement (modified International Bone Marrow Transplant Registry [IBMTR] Severity Stage 1 to 4 [>500 mL diarrhea/day]), with or without other organ system involvement.

5. Willing to undergo or must have had a lower GI biopsy within 7 days of informed consent to confirm GI GvHD. Biopsy results are not needed to initiate treatment; however, if biopsy results are not consistent with aGvHD, treatment with GLASSIA will be discontinued.

6. Participants must be receiving systemic corticosteroids. Treatment with methylprednisolone/systemic steroids must have been initiated within 72 hours prior to the first dose of study treatment after enrollment

7. Evidence of myeloid engraftment (absolute neutrophil count ≥0.5 x 10^9/L)

8. Lower GI GvHD manifested by diarrhea must have other causes of diarrhea ruled out (eg, negative for Clostridium difficile or cytomegalovirus [CMV] infection or oral magnesium administration)

9. Karnofsky Performance Score ≥50%

10. If female of childbearing potential, participant presents with a negative blood pregnancy test

11. Females of childbearing potential with a fertile male sexual partner must agree to employ adequate contraception for the duration of the study.

12. Males must use adequate contraception and must not donate sperm for the duration of the study.

13. Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria

1. Participant with manifestations of chronic GvHD

2. Participant with acute/chronic GvHD overlap syndrome

3. Participant whose GvHD developed after donor lymphocyte infusion

4. Participant with myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to the first dose of study treatment, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant

5. Participant with evidence of recurrent malignancy

6. Participant with veno-occlusive disease (ie, sinusoidal obstruction syndrome)

7. Participant receiving GvHD treatment other than continued prophylaxis (eg, cyclosporine and/or mycophenolate mofetil, etc) or corticosteroid therapy. In addition, a participant who received the first dose of corticosteroid therapy for acute GvHD with lower GI involvement more than 72 hours before the first dose of study treatment is not eligible for the study

8. Participant with severe sepsis involving at least 1 organ failure

9. Participant who is seropositive or positive in the nucleic acid test for human immunodeficiency virus (HIV)

10. Participant with active hepatitis B or C

11. Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study

12. If female, participant is pregnant or lactating at the time of enrollment, or has plans to become pregnant during the study

13. Participant with a serious medical or psychiatric illness likely to interfere with participation in the study

14. Participant is a family member or employee of the investigator

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kamada, Ltd.

INDUSTRY

Sponsor Role: collaborator

Baxalta now part of Shire

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Shire

Locations

Georgia Cancer Center

Augusta, Georgia, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

471501

Identifier Type: -

Identifier Source: org_study_id